Behind closed doors.

The article focuses on developments related to confidential business information (CBI) in the biotechnology and pharmaceutical industries as of June 2014. Topics highlighted include efforts of researchers, government regulators and companies to redefine what CBI is, increase in criticism of the industries' data disclosure practices and legal protection of trade secrets. Also discussed is the industries' protection of human data related to safety and efficacy of drugs.